To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
LRRK2 Antibody (MJFF5)
Antibody
Rabbit monoclonal antibody directed against wild-type LRRK2. The antibody was mapped to the LRR domain of LRRK2 (AA 1035-1239).
LRRK2 Antibody (N241A/34)
Antibody
Mouse monoclonal antibody directed against wild-type LRRK2 using a fragment of LRRK2 (AA 970-2527).
LRRK2 Antibody (SIG-39840)
Antibody
Mouse monoclonal antibody generated in a mouse lacking endogenous LRRK2 protein using a peptide of LRRK2 (AA 2069-2087).
LRRK2 Antibody (UDD3)
Antibody
Rabbit monoclonal antibody directed against the N-terminus (LRRK2(100-500)) of wild-type LRRK2. This antibody has been found to be superior in immunoprecipitation of LRRK2 from a variety of cell lysates and tissues.
LRRK2 D1994A Mouse
Mouse Model
Mice expressing the D1994A mutant (kinase-dead) form of LRRK2. RRID:IMSR_JAX:021830
LRRK2 D1994A/G2019S Mouse
Mouse Model
Transgenic mice overexpressing both a mutant form D1994A and G2019S of human LRRK2 directed by its endogenous promoter/enhancer regions on the BAC transgene.
Please note: Although founders were positively identified through genotyping and exhibited robust mRNA expression, these projects were halted due to a lack of any appreciable protein expression.
LRRK2 D1994A/R1441G Mouse
Mouse Model
Transgenic mice overexpressing both a mutant form D1994A and R1441G of human LRRK2 directed by its endogenous promoter/enhancer regions on the BAC transgene.
Please note: Although founders were positively identified through genotyping and exhibited robust mRNA expression, these projects were halted due to a lack of any appreciable protein expression.
LRRK2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in LRRK2, including heterozygous and homozygous N2081D, R1441G, I2020T, G2019S, and Y1699C mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP).*Heterozygous and homozygous R1398H and L1795F mutations are currently in development. Estimated Availability: Q1 2026.
LRRK2 Full-Length Protein (Human)
Protein
Full-Length human LRRK2 protein generated in vitro and assessed for kinase activity.
LRRK2 G2019S KI MEF
Immortalized Cell
Mouse embryonic fibroblast line with knockin of the LRRK2 G2019S mutation.
Expected availability: Late 2025
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic